Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Skip to main content

Synodos for NF1: Call for Applications

Synodos is a new application-based consortium which is encouraging highly collaborative, interdisciplinary, multi-institutional, translational research involving basic, applied, and clinical science. Synodos for NF2 was the first fully-integrated neurofibromatosis type 2 (NF2) research project to directly advance the NF2 field through translational and clinical research.

The Children’s Tumor Foundation is now embarking upon a new consortium in Synodos for NF1. The end goal is to fund new approaches to the diagnosis and treatment of NF1, especially directed at low grade gliomas and innovative ways to make better, faster decisions regarding the potential efficacy of treatments.

Synodos requires collaboration between basic biologists, animal pharmacologists, imagers, clinicians, and industry partners who will work together in this next, and perhaps most important, step in finding treatments and a cure for NF1.

For more information and application specifications, please click here.

Full applications due by 5:00 p.m. EST on Friday, January 16, 2015.

Close Menu